retatrutide type 2 diabetes trial dosing Medscape | The investigational triple GLP-1/GIP/glucagon receptor agonist produced significant weight loss and A1c reduction in people Retatrutide Weight Loss Treatment Explained

Elective procedures: if daily dosing, DC on the day of surgery

The glucagon receptor, again, appears to be the differentiator

Hamel, KFF Health Tracking Poll May 2024: The Publics Use and Views of GLP-1 Drugs

Highlighted text about two NHS colleagues This story never happened

Rybelsus, the only oral GLP-1, is expected to be joined by Orforglipron by 2027-28

In the main per-protocol analyses, participants were followed from the index date to first mutually exclusive incidence of SIS, discontinuation of study drug (defined as more than 60 days without drug supply), initiation of other study drug, or switch to other glucose-lowering drug (defined as filling a prescription for any glucose-lowering drug other than the baseline treatment or metformin and not refilling the assigned drug for 60 days), death, or end of follow-up